Clinical Trial Update: Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update describes a head-to-head Phase 2/3 study comparing NABPLAGEM to Nab-Paclitaxel plus Gemcitabine in patients with advanced or metastatic pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• NABPLAGEM
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Pancreatic Cancer, Advanced or Metastatic, BRCA1/2 Mutation | Phase 2, Phase 3 | Status: RECRUITING